Response Competitors

Summary

Response Oncology competes with SEI Investments, Seadrill, Freedom Holding, Morgan Stanley, and Sable Offshore; as well as few others. The company conducts business under Health Care Providers & Services sector and is part of Health Care industry. Analyzing Response Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Response Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Response Oncology competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
0.00	0.00	0.00

Details

Intrinsic

Valuation

Low	Real	High
0.00	0.00	0.00

Details

Response Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Response Oncology and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Response and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Response Oncology does not affect the price movement of the other competitor.

	SEIC	SDRL	FRHC	MS	SOC	STEP	RIG	PPYAU
SEIC		0.06	0.97	0.92	-0.28	0.75	-0.45	0.3	SEIC
SDRL	0.06		-0.05	0.02	0.71	0.01	0.67	0.03	SDRL
FRHC	0.97	-0.05		0.86	-0.34	0.67	-0.55	0.22	FRHC
MS	0.92	0.02	0.86		-0.32	0.88	-0.32	0.3	MS
SOC	-0.28	0.71	-0.34	-0.32		-0.23	0.63	-0.12	SOC
STEP	0.75	0.01	0.67	0.88	-0.23		-0.2	0.37	STEP
RIG	-0.45	0.67	-0.55	-0.32	0.63	-0.2		-0.01	RIG
PPYAU	0.3	0.03	0.22	0.3	-0.12	0.37	-0.01		PPYAU
	SEIC	SDRL	FRHC	MS	SOC	STEP	RIG	PPYAU

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

FRHC	+ 0.97	SEIC
MS	+ 0.92	SEIC
STEP	+ 0.88	MS
MS	+ 0.86	FRHC
STEP	+ 0.75	SEIC
SOC	+ 0.71	SDRL

High negative correlations

RIG	- 0.55	FRHC
RIG	- 0.45	SEIC
SOC	- 0.34	FRHC
RIG	- 0.32	MS
SOC	- 0.32	MS
SOC	- 0.28	SEIC

Risk-Adjusted Indicators

There is a big difference between Response Stock performing well and Response Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Response Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
SEIC	0.80	0.30	0.31	0.42	0.46	(0.97)	1.57	(1.56)	7.23
SDRL	1.87	(0.12)	0.00	(0.11)	0.00	0.00	3.83	(3.21)	13.86
FRHC	1.30	0.48	0.26	1.09	1.12	(1.41)	3.26	(2.17)	9.39
MS	1.20	0.28	0.35	0.20	0.49	(1.59)	3.08	(1.78)	13.93
SOC	3.65	(0.22)	0.00	(0.08)	0.00	0.00	6.22	(8.18)	31.37
STEP	1.51	0.34	0.15	(2.76)	1.50	(1.68)	3.05	(2.13)	16.32
RIG	2.36	(0.30)	0.00	(0.33)	0.00	0.00	5.18	(5.25)	14.43
PPYAU	0.13	0.02	0.00	(0.56)	0.00	0.00	0.00	0.00	5.02

Unable to evaluate fundamental data of [SEIC, SDRL, FRHC, MS, SOC, STEP, RIG, PPYAU] at this time. Please try again later

All Fundamental Data

Response Oncology Competitive Analysis

The better you understand Response Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Response Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Response Oncology's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	SEIC	SDRL	FRHC	MS	SOC	STEP	RIG	PPYAU
	0.71 85.12 SEI	0.82 37.31 Seadrill	1.77 131.18 Freedom	1.00 127.74 Morgan	2.29 21.33 Sable	2.73 63.64 Stepstone	1.61 3.67 Transocean	0.00 11.19 Papaya
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Not too volatile	Very steady	Slightly risky	Very steady
Market Performance (90 Days Performance)	Solid	Very Weak	Solid	Solid	Very Weak	OK	Very Weak	Insignificant
Odds of Financial Distress (Probability Of Bankruptcy)	Low	Very Small	Low	Very Low	Average	Low	About Average	High
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Over Valued	Over Valued	Under Valued	Over Valued	Under Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Buy	Strong Buy	Strong Sell	Buy	Strong Buy	Buy	Buy	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Buy	Strong Hold	Strong Buy	Strong Buy	Strong Sell	Cautious Hold	Hold	Hold
Current Ratio	4.43 X	2.51 X	1.18 X	2.00 X	N/A	0.87 X	1.64 X	0.08 X
Net Asset	2.52 B	4.22 B	8.3 B	1.19 T	63.92 M	3.79 B	20.25 B	25.66 M
Profit Margin	0.27 %	0.29 %	0.26 %	0.19 %	N/A	0.05 %	(0.19) %	N/A
EBITDA	424.52 M	494 M	865.11 M	23.55 B	(4.92 M)	249.86 M	501 M	3.98 M
Operating Margin	0.27 %	0.15 %	0.27 %	0.33 %	N/A	0.23 %	0.16 %	N/A
Current Valuation	10.07 B	2.48 B	6.53 B	66.67 B	2.14 B	4.89 B	9.74 B	110.9 M
Price To Book	4.66 X	0.83 X	6.42 X	2.19 X	11.98 X	12.13 X	0.31 X	N/A
Retained Earnings	762.59 M	501 M	998.74 M	98 B	(55.58 M)	13.77 M	(4.03 B)	(20.53 M)
Current Asset	1 B	2.94 B	N/A	N/A	N/A	N/A	4.79 B	N/A
Five Year Return	1.18 %	N/A	N/A	2.52 %	N/A	N/A	N/A	N/A
Beta	0.97	1.58	1.02	1.34	0.26	1.26	2.79	-0.019
Number Of Employees	5.06 K	2.5 K	7.15 K	80 K	106	1.05 K	5.43 K	N/A
Shares Outstanding	128.91 M	64.66 M	60.61 M	1.61 B	64.85 M	75.76 M	875.8 M	N/A
Cash Flow From Operations	447.03 M	287 M	(1.06 B)	(33.54 B)	(3.84 M)	161.52 M	164 M	(4.36 M)
Annual Yield	0.01 %	N/A	N/A	0.03 %	N/A	0.02 %	N/A	N/A
Total Debt	25.35 M	608 M	3.07 B	276.39 B	7.51 M	268.56 M	7.85 B	2.62 M
Return On Equity	0.25	0.14	0.31	0.11	-6.46	0.0867	-0.0606	N/A
Z Score	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return On Asset	0.13	0.0404	0.0427	0.0094	-0.0894	0.0307	0.0061	-0.0205
Book Value Per Share	18.29 X	44.60 X	20.81 X	58.25 X	1.88 X	5.47 X	11.68 X	(1.83) X
Number Of Shares Shorted	1.34 M	4.18 M	352.98 K	15.33 M	3.01 M	2.4 M	145.12 M	N/A
Current Liabilities	224.48 M	3.47 B	N/A	N/A	N/A	N/A	2.67 B	N/A
Total Asset	2.52 B	4.22 B	8.3 B	1.19 T	63.92 M	3.79 B	20.25 B	25.66 M
Debt To Equity	0.01 %	0.68 %	1.69 %	3.42 %	N/A	0.08 %	0.64 %	3.12 %
Short Ratio	2.07 X	4.20 X	3.65 X	2.24 X	8.77 X	4.18 X	7.56 X	0.03 X
Target Price	78.8	54.78	76.0	126.67	27.33	70.79	5.31	N/A
Last Dividend Paid	0.92	N/A	N/A	3.55	N/A	0.87	N/A	N/A
Shares Owned By Institutions	73.00 %	84.84 %	1.01 %	62.12 %	51.42 %	93.80 %	71.36 %	0.02 %
Market Capitalization	10.97 B	2.43 B	8.09 B	205.79 B	1.46 B	7.73 B	3.21 B	N/A
Price To Earning	19.70 X	0.98 X	16.11 X	13.51 X	N/A	5.11 X	(3.44) X	N/A
Price To Earnings To Growth	1.32 X	(0.04) X	N/A	3.70 X	N/A	2.35 X	(22.91) X	N/A
Price To Sales	5.35 X	1.67 X	6.20 X	3.53 X	N/A	9.66 X	0.97 X	N/A
Net Income	462.26 M	300 M	375.54 M	9.09 B	(32.18 M)	58.09 M	(954 M)	1.89 M
Earnings Per Share	4.15 X	5.78 X	5.70 X	6.58 X	(2.86) X	0.61 X	(0.76) X	N/A
Shares Owned By Insiders	23.95 %	N/A	70.95 %	23.67 %	31.72 %	19.06 %	16.67 %	N/A
Revenue	1.92 B	1.47 B	1.64 B	53.61 B	N/A	711.63 M	2.83 B	N/A
Working Capital	1.13 B	769 M	2.11 B	N/A	(16.41 M)	(32.15 M)	729 M	(21.07 M)
Cash And Equivalents	791.44 M	336 M	2.15 B	122.72 B	N/A	106.35 M	683 M	1.19 M
Cash Per Share	5.87 X	6.72 X	36.11 X	325.70 X	N/A	1.73 X	1.32 X	0.03 X
Gross Profit	1.58 B	277 M	468.93 M	46.44 B	N/A	562.83 M	907 M	N/A
Day Typical Price	85.34	37.04	131.87	127.87	21.42	63.43	3.64	11.19
Accumulation Distribution	9309.86	23780.36	2376.42	84343.22	45047.46	0.038	1.1 M	N/A
Market Facilitation Index	0.0	0.0	0.0	N/A	0.0	2.45	N/A	N/A
Daily Balance Of Power	(0.62)	(0.31)	(0.66)	(0.85)	(0.63)	0.6898	(0.38)	0.0
Period Momentum Indicator	(0.61)	(0.31)	(2.37)	(1.29)	(0.50)	1.69	(0.06)	N/A
Rate Of Daily Change	0.99	0.99	0.98	0.99	0.98	1.03	0.98	1.0
Day Median Price	85.46	36.91	132.22	127.94	21.47	63.33	3.62	11.19
Price Action Indicator	(0.64)	0.25	(2.22)	(0.85)	(0.39)	1.16	0.02	N/A
Coefficient Of Variation	326.08	(3,700)	341.28	493.22	(4,244)	640.68	(1,224)	1882.61
Mean Deviation	0.8012	1.87	1.3	1.2	3.65	1.51	2.36	0.125
Jensen Alpha	0.3016	(0.12)	0.4771	0.2759	(0.22)	0.3372	(0.30)	0.0173
Total Risk Alpha	0.2559	(0.28)	0.3642	0.2334	(0.52)	0.1567	(0.49)	(0.02)
Sortino Ratio	0.3087	N/A	0.2552	0.3498	N/A	0.1516	N/A	N/A
Downside Variance	0.8911	N/A	3.06	0.9065	N/A	3.23	N/A	N/A
Standard Deviation	1.17	2.49	1.75	1.98	4.95	2.18	2.99	0.4843
Kurtosis	5.08	3.03	0.9292	16.26	4.22	7.02	0.3966	23.32
Potential Upside	1.57	3.83	3.26	3.08	6.22	3.05	5.18	N/A
Treynor Ratio	0.4238	(0.11)	1.09	0.1964	(0.08)	(2.76)	(0.33)	(0.56)
Maximum Drawdown	7.23	13.86	9.39	13.93	31.37	16.32	14.43	5.02
Variance	1.37	6.18	3.08	3.91	24.46	4.75	8.95	0.2346
Market Risk Adjusted Performance	0.4338	(0.10)	1.1	0.2064	(0.07)	(2.75)	(0.32)	(0.55)
Risk Adjusted Performance	0.2261	(0.01)	0.2182	0.1533	(0.01)	0.1198	(0.05)	0.0335
Skewness	1.32	1.28	0.1175	3.32	(1.32)	1.35	0.5318	0.6124
Semi Deviation	0.4599	N/A	1.12	0.4944	N/A	1.5	N/A	N/A
Information Ratio	0.2489	(0.05)	0.2544	0.1685	(0.04)	0.125	(0.10)	(0.09)
Value At Risk	(1.56)	(3.21)	(2.17)	(1.78)	(8.18)	(2.13)	(5.25)	N/A
Expected Short fall	(0.97)	N/A	(1.41)	(1.59)	N/A	(1.68)	N/A	N/A
Downside Deviation	0.944	N/A	1.75	0.9521	N/A	1.8	N/A	N/A
Semi Variance	0.2115	N/A	1.25	0.2444	N/A	2.24	N/A	N/A

Response Oncology Competition Performance Charts

Five steps to successful analysis of Response Oncology Competition

Response Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Response Oncology in relation to its competition. Response Oncology's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Response Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Response Oncology's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Response Oncology, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Response Oncology position

In addition to having Response Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Beer and Liquor Thematic Idea Now

Beer and Liquor

Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Beer and Liquor theme has 32 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Beer and Liquor Theme or any other thematic opportunities.

View All Next

Launch

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Other Consideration for investing in Response Stock

If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.

	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC